Bookmark and Share

Compound Summary for: CID 5329102


Also known as: Sutent; 557795-19-4; SU-11248; sunitinibum; SU11248; Sunitinib (INN); Su-011248; SU 11248; UNII-V99T50803M
Molecular Formula: C22H27FN4O2   Molecular Weight: 398.473783   InChIKey: WINHZLLDWRZWRT-ATVHPVEESA-N
Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.   From: DrugBank
Show subcontent titlesTable of Contents
Related Records
show all 3 sub-sections (Related Compounds with Annotation, Related Compounds, Related Substances)
Use and Manufacturing
Biomedical Effects and Toxicity
Safety and Handling
Exposure Standards and Regulations
Biomolecular Interactions and Pathways
Biological Test Results
Chemical and Physical Properties
_ _